Pharmacokinetics.
Complex, yet fascinating.

This key branch of pharmacology is dedicated to determining the fate of substances administered to a living organism, including that of any chemical xenobiotic such as pharmaceutical drugs, pesticides, and food additives. Simply put, the study of how a drug moves into, through, and out of the body is known as pharmacokinetics (PK).

Focused primarily on the study of the time-course of drug absorption, distribution, metabolism, and excretion, the application of pharmacokinetic principles contribute significantly to the safe and effective therapeutic management of drugs in patients and are therefore an essential stage in all drug development.

By describing how the body affects a specific xenobiotic after administration, outlining its absorption and distribution, as well as reporting the metabolic changes of the substance in the body (e.g. by metabolic enzymes), and indeed understanding the effects and routes of excretion of the metabolites of the drug, it’s possible to build a much clearer picture of how dosage, route of administration and absorption relate, and can be optimized for best efficacy.

Furthermore, all these above stages of course influence the course of concentration over time, or in scientific terms, the basic pharmacokinetic curve. As the main objective in running such studies in this area, obtaining the knowledge of when maximal concentration (Cmax) is achieved, (Tmax) the time it takes to achieve it, and clear data on (AUC) the area under the curve, you can have confidence in the way your medicine will be dealt with by the body.

Comprising teams of world-leading experts in the field of bioanalytics, QUINTA-ANALYTICA offers an exceptional array of testing, including full PK studies. Operating globally yet retaining a local approach, speak to the team at Quinta to see how they can help your next drug to market quicker, and more professionally than ever before.

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.